AbbVie (ABBV.N): ABBV-466 raises the potential for deeper Crohn's responses and Skyrizi lifecycle extension

ABBV-466's phase 2a TARGET-CD results support dual IL-23p19 (Skyrizi) and α4β7 (trosunilimab) inhibition as a potential route to deeper efficacy than either pathway alone. Endoscopic remission reached 30.2% at Week 12 versus 21.3% with Skyrizi and 18.0% with trosunilimab, with the advantage widening at Week 24 to 40.5% versus 22.4% and 20.0%, respectively. The results are particularly encouraging in a heterogeneous, heavily pretreated population, while comparable serious-adverse-event rates provide initial reassurance on combination safety. However, the open-label design, modest arm sizes, and lack of placebo warrant caution, and randomized confirmation remains necessary. If validated, ABBV-466 could address patients requiring deeper disease control and provide a potential lifecycle-management strategy for Skyrizi beyond its expected LOE (~2033). Overall, the data add attractive IBD optionality, though additional internal assets and BD will likely remain necessary to more fully strengt